Enlivex Therapeutics stock reports cancelled financing

Enlivex Therapeutics stock stood at USD 0.64 on Nasdaq on September 23, 2026, down 0.99 percent from the previous close. The company had a market capitalization of USD 10,772,490, while its 52-week range stretched from USD 0.57 to USD 27.15.

RAIN financing ends

Enlivex cancelled a proposed private placement involving 66,666,667 ordinary shares payable in RAIN tokens. According to GlobeNewswire on September 22, 2026, the agreement with the Rain Foundation was terminated under Enlivex contractual rights.

The financing required shareholder approval before completion. The termination means Enlivex will not proceed with the proposed share issuance or seek approval for the transaction, removing a planned equity financing event from the company calendar.

Stock remains near yearly low

The market data show a sharp long-term contrast. At USD 0.64, Enlivex shares were 97.64 percent below the 52-week high of USD 27.15, while the current price was USD 0.07 above the 52-week low of USD 0.57.

Trading volume reached 592,379 shares on September 23, 2026, compared with an average volume of 301,776 shares. That difference places the session volume 96.3 percent above the average and gives the financing decision a market context beyond the daily move of 0.99 percent.

Clinical pipeline meets treasury strategy

Enlivex describes itself as a quality longevity company powered by a prediction markets treasury. Its clinical program is advancing Allocetra, an immunotherapy targeting inflammatory conditions associated with aging, with age-related osteoarthritis identified as a primary focus.

For investors, the central distinction is between the clinical pipeline and the treasury strategy. The cancelled 66,666,667-share transaction changes the proposed financing path, while the Nasdaq quotation remains the clearest daily measure of how the market values Enlivex.

ENLV holds at USD 0.64

Enlivex Therapeutics stock stood at USD 0.64 on Nasdaq on September 23, 2026, with a daily change of minus 0.99 percent. The company remains a clinical-stage biotechnology issuer whose market capitalization was USD 10,772,490 as of the same date.